BridgeBio Pharma Inc (BBIO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
BridgeBio Pharma Inc stock (BBIO) is currently trading at $71.61. BridgeBio Pharma Inc PS ratio (Price-to-Sales) is 26.46. Analyst consensus price target for BBIO is $100.64. WallStSmart rates BBIO as Sell.
- BBIO PE ratio analysis and historical PE chart
- BBIO PS ratio (Price-to-Sales) history and trend
- BBIO intrinsic value — DCF, Graham Number, EPV models
- BBIO stock price prediction 2025 2026 2027 2028 2029 2030
- BBIO fair value vs current price
- BBIO insider transactions and insider buying
- Is BBIO undervalued or overvalued?
- BridgeBio Pharma Inc financial analysis — revenue, earnings, cash flow
- BBIO Piotroski F-Score and Altman Z-Score
- BBIO analyst price target and Smart Rating
BridgeBio Pharma Inc
📊 No data available
Try selecting a different time range
Smart Analysis
BridgeBio Pharma Inc (BBIO) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
BridgeBio Pharma Inc (BBIO) Key Strengths (3)
Revenue surging 2521.00% year-over-year
101.60% of shares held by major funds and institutions
Large-cap company with substantial market presence
Supporting Valuation Data
BridgeBio Pharma Inc (BBIO) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 26.5x annual revenue
Very expensive at 123.7x book value
Supporting Valuation Data
BridgeBio Pharma Inc (BBIO) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.7/10) while 5 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 2521.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (26.46), Price/Book (123.68) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -1790.00%, Operating Margin at -83.30%, Profit Margin at -144.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1790.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 2521.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BBIO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BBIO's Price-to-Sales ratio of 26.46x trades at a deep discount to its historical average of 323.74x (16th percentile). The current valuation is 98% below its historical high of 1651.91x set in Dec 2020, and 33% above its historical low of 19.9x in May 2022. Over the past 12 months, the PS ratio has compressed from ~30.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for BridgeBio Pharma Inc (BBIO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
BridgeBio Pharma Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 502M with 2521% growth year-over-year. The company is currently unprofitable, posting a -144.4% profit margin.
Key Findings
Revenue growing at 2521% YoY, reaching 502M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of -0.96 indicates a conservative balance sheet with 643M in cash.
The company is unprofitable with a -144.4% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -61M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can BridgeBio Pharma Inc maintain 2521%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact BridgeBio Pharma Inc.
Bottom Line
BridgeBio Pharma Inc is a high-conviction growth story with revenue accelerating at 2521% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -144.4% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About BridgeBio Pharma Inc(BBIO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.